Solifenacin to relieve ureteral stent-related symptoms:A randomized, double-blinded placebo-controlled study
Phase 4
Recruiting
- Conditions
- reteral stent-related symptoms after ureteroscopic stone manipulation.Ureteral stent-related symptoms after ureteroscopic stone manipulation.Renal and Urogenital - Other renal and urogenital disorders
- Registration Number
- ACTRN12610001022055
- Lead Sponsor
- Mennonite Christian Hospital, Taiwan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
From 01/10/2010 to 30/10/2011, all patients with unilateral ureteral stones to be treated with ureteroscopy where temporary stenting is indicated will be considered for enrollment in the study.
Exclusion Criteria
Patients who had significant ureteral trauma, a preexisting ureteral stent, another secondary surgical procedure that would have impacted patient comfort, ie transurethral resection of the prostate or of bladder tumor, or urinary infection or chronic pain history will be excluded from study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of ureteral stent-related symptoms will be assessed using the ureteral stent symptom questionnaire (USSQ)[1, 3 , and 14 days after ureteral stent insertion.]
- Secondary Outcome Measures
Name Time Method il[Nil]